| Thromboembolism |
1 |
1 |
| Meta-Analysis |
0 |
0.67 |
| Cardiovascular Risk Management |
0 |
0.54 |
| Cerebrovascular Accident |
0 |
0.52 |
| Pulmonary Embolism |
0 |
0.48 |
| Psoriasis |
0 |
0.42 |
| Dermatitis |
0 |
0.39 |
| Dermatoses |
0 |
0.34 |
| Venous Thromboembolism (VTE) |
0 |
0.99 |
| Acute Coronary Syndrome |
0 |
0.29 |
| Deep Venous Thrombosis |
0 |
0.29 |
| Heart Failure (HF) |
0 |
0.29 |
| Washington DC |
0 |
0.24 |
| Angina Pectoris |
0 |
0.23 |
| Myocardial Infarction (MI) |
0 |
0.23 |
| Embolism |
0 |
0.22 |
| Heart |
0 |
0.22 |
| Thrombosis |
0 |
0.22 |
| Washington |
0 |
0.22 |
| Rheumatoid Arthritis |
0 |
0.19 |
| Acute Myocardial Infarction (MI) |
0 |
0.16 |
| Thrombus |
0 |
0.16 |
| Healthcare and Medical Technology |
0 |
0.14 |
| Arthritis |
0 |
0.11 |
| Atopic Dermatitis |
0 |
0.11 |
| Blood |
0 |
0.11 |
| Cancer |
0 |
0.11 |
| Child |
0 |
0.11 |
| Clinical Research |
0 |
0.11 |
| Infarction |
0 |
0.11 |
| Statistics |
0 |
0.11 |
| Tumor |
0 |
0.11 |
| Unstable Angina |
0 |
0.11 |
| Vein |
0 |
0.11 |